Seth Klarman Finch Therapeutics Group, Inc. Transaction History

Baupost Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.34 - $0.56 $340,000 - $560,000	1,000,000 Added 98.13%	2,019,008 $793,000
Q4 2022 Feb 13, 2023	SELL	$0.36 - $56.4 $37,476 - $5.87 Million	-104,100 Reduced 9.27%	1,019,008 $489,000
Q1 2022 May 13, 2022	SELL	$5.02 - $10.47 $45,907 - $95,748	-9,145 Reduced 0.81%	1,123,108 $5.65 Million
Q4 2021 Feb 11, 2022	SELL	$8.95 - $16.88 $679,358 - $1.28 Million	-75,906 Reduced 6.28%	1,132,253 $11.3 Million
Q1 2021 May 14, 2021	BUY	$15.54 - $21.32 $18.8 Million - $25.8 Million	1,208,159 New	1,208,159 $18.9 Million

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $572M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Baupost Group LLC, based on Form 13F filings with the SEC.

Stay updated on Baupost Group LLC and Seth Klarman with notifications on news.